LifeVantage Corporation (LFVN)

Market Cap	61.21M -69.6%
Revenue (ttm)	210.05M -1.0%
Net Income	7.86M +7.1%
EPS	0.60 +6.9%
Shares Out	12.80M
PE Ratio	7.95
Forward PE	8.15
Dividend	$0.18 (3.77%)
Ex-Dividend Date	Mar 2, 2026

Volume	172,453
Open	4.580
Previous Close	4.570
Day's Range	4.580 - 4.810
52-Week Range	3.900 - 15.000
Beta	0.39
Analysts	Strong Buy
Price Target	11.00 (+130.13%)
Earnings Date	May 5, 2026

About LFVN

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre and pro-biotics and skin and hair care products internationally. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, ...

• Industry: Packaged Foods
• Sector: Consumer Staples
• CEO: Steven Fife
• Employees: 238
• Stock Exchange: NASDAQ
• Ticker Symbol: LFVN
• Website: https://www.lifevantage.com

Financial Performance

In fiscal year 2025, LifeVantage's revenue was $228.53 million, an increase of 14.17% compared to the previous year's $200.16 million. Earnings were $9.81 million, an increase of 233.84%.

Analyst Summary

According to one analyst, the rating for LFVN stock is "Strong Buy" and the 12-month stock price target is $11.0.

Price Target

$11.0

(130.13% upside)

Analyst Consensus: Strong Buy